Hiromi Nyuzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiromi Nyuzuki has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Nagasaki
Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
7 shared publications - Takeshi Ikeuchi
Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
5 shared publications - Jun Tohyama
Department of Child Neurology NHO Nishiniigata Chuo Hospital Niigata Japan
4 shared publications - Shota Hiroshima
Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
3 shared publications - Akihiko Saitoh
Department of Pediatrics Niigata University Graduate School of Medical and Dental Sciences Niigata Japan
2 shared publications Go Hasegawa
Department of Pathology, Uonuma Kikan Hospital, Niigata, Japan
2 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (9) , e70285
Biallelic VPS41 Variants in Autosomal Recessive Spinocerebellar Ataxia 29 Resolved by Long‐Read Sequencing and RNA Analysis
Background: Biallelic variants in VPS41 , encoding a subunit of the HOPS complex, cause autosomal recessive spinocerebellar ataxia 29 (SCAR29), a rare neurodevelopmental disorder with an incompletely defined phenotypic and molecular spectrum. Methods: We investigated a 24‐year‐old man with cerebellar ataxia, hypotonia, and intellectual disability. Exome sequencing identified four candidate VPS41 variants. Because maternal DNA was unavailable, long‐read genome sequencing was performed to determine allelic configuration, followed by RNA and protein analyses. Results: In addition to typical SCAR29 features, the patient showed previously unreported findings, including swan‐neck deformities and pes cavus. Long‐read genome sequencing demonstrated that two VPS41 variants were in trans. RNA analysis revealed distinct splicing consequences: one allele produced an out‐of‐frame transcript predicted to undergo nonsense‐mediated decay, whereas the other generated an in‐frame exon‐skipped transcript. These complementary defects reduced VPS41 expression at both transcript and protein levels, supporting pathogenicity and variant reclassification. Conclusion: Our findings expand the phenotypic spectrum of VPS41 ‐related disease and highlight the value of long‐read allelic resolution in clarifying pathogenic mechanisms in rare genetic disorders.
- 27 August 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (9) , e70285
Open AccessBiallelic VPS41 Variants in Autosomal Recessive Spinocerebellar Ataxia 29 Resolved by Long‐Read Sequencing and RNA Analysis
Background: Biallelic variants in VPS41 , encoding a subunit of the HOPS complex, cause autosomal recessive spinocerebellar ataxia 29 (SCAR29), a rare neurodevelopmental disorder with an incompletely defined phenotypic and molecular spectrum. Methods: We investigated a 24‐year‐old man with cerebellar ataxia, hypotonia, and intellectual disability. Exome sequencing identified four candidate VPS41 variants. Because maternal DNA was unavailable, long‐read genome sequencing was performed to determine allelic configuration, followed by RNA and protein analyses. Results: In addition to typical SCAR29 features, the patient showed previously unreported findings, including swan‐neck deformities and pes cavus. Long‐read genome sequencing demonstrated that two VPS41 variants were in trans. RNA analysis revealed distinct splicing consequences: one allele produced an out‐of‐frame transcript predicted to undergo nonsense‐mediated decay, whereas the other generated an in‐frame exon‐skipped transcript. These complementary defects reduced VPS41 expression at both transcript and protein levels, supporting pathogenicity and variant reclassification. Conclusion: Our findings expand the phenotypic spectrum of VPS41 ‐related disease and highlight the value of long‐read allelic resolution in clarifying pathogenic mechanisms in rare genetic disorders.
- Open Access
- 14 June 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (4) , e70082
Long‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study
Sodium phenylbutyrate (NaPBA) is used for nitrogen scavenging in urea cycle disorders (UCDs), but its volume, palatability, and sodium load affect adherence and ammonia control. Glycerol phenylbutyrate (GPB) offers an alternative option with demonstrated improvements in metabolic control and palatability. For a Japanese perspective, we undertook an open‐label, multicentre, prospective Phase 3 study of efficacy, pharmacokinetics (PK), and safety. In a switch‐over, 15 patients received NaPBA for 7 days, then GPB for 7 days. Primary endpoint: 24‐h blood ammonia AUC (AUC NH3,0–24 ). Secondary endpoints: blood ammonia and glutamine concentration; PK of scavenger metabolites in blood and urine; safety. Patients then received GPB for up to 12 months. For GPB and NaPBA, respectively, mean (SD) AUC NH3,0–24 was 627 (198) and 757 (307) μmol·h/L (ratio 0.849; 95% CI 0.723–0.997). Mean peak and mean blood ammonia were 37 and 26 μmol/L versus 52 and 32 μmol/L. Mean plasma AUC 0–24 for phenylbutyrate (PBA), phenylacetate (PAA), and phenylacetylglutamine (PAGN) were 470, 1420, and 836 versus 425, 984, and 741 μg·h/mL. Mean PBA metabolite fluctuation was 297% versus 366%. One adverse event (hyperammonaemia) led to discontinuation in each treatment arm. In the extension ( n = 14), mean (SD) blood ammonia at Month 12 was 21 (8) μmol/L. No new safety findings were observed. GPB demonstrated effective control of blood ammonia with a favourable safety profile. It offers a practical and clinically advantageous alternative to NaPBA, extending previous evidence to Japanese individuals with UCDs. Trial registration: jRCT2071220110.
- 14 June 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (4) , e70082
Open AccessLong‐Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch‐Over and 12‐Month Extension Study
Sodium phenylbutyrate (NaPBA) is used for nitrogen scavenging in urea cycle disorders (UCDs), but its volume, palatability, and sodium load affect adherence and ammonia control. Glycerol phenylbutyrate (GPB) offers an alternative option with demonstrated improvements in metabolic control and palatability. For a Japanese perspective, we undertook an open‐label, multicentre, prospective Phase 3 study of efficacy, pharmacokinetics (PK), and safety. In a switch‐over, 15 patients received NaPBA for 7 days, then GPB for 7 days. Primary endpoint: 24‐h blood ammonia AUC (AUC NH3,0–24 ). Secondary endpoints: blood ammonia and glutamine concentration; PK of scavenger metabolites in blood and urine; safety. Patients then received GPB for up to 12 months. For GPB and NaPBA, respectively, mean (SD) AUC NH3,0–24 was 627 (198) and 757 (307) μmol·h/L (ratio 0.849; 95% CI 0.723–0.997). Mean peak and mean blood ammonia were 37 and 26 μmol/L versus 52 and 32 μmol/L. Mean plasma AUC 0–24 for phenylbutyrate (PBA), phenylacetate (PAA), and phenylacetylglutamine (PAGN) were 470, 1420, and 836 versus 425, 984, and 741 μg·h/mL. Mean PBA metabolite fluctuation was 297% versus 366%. One adverse event (hyperammonaemia) led to discontinuation in each treatment arm. In the extension ( n = 14), mean (SD) blood ammonia at Month 12 was 21 (8) μmol/L. No new safety findings were observed. GPB demonstrated effective control of blood ammonia with a favourable safety profile. It offers a practical and clinically advantageous alternative to NaPBA, extending previous evidence to Japanese individuals with UCDs. Trial registration: jRCT2071220110.
- Open Access
- 12 June 2026
- Published by Springer Nature in Human Genome Variation
Post-mortem diagnosis of CACT deficiency with a novel SLC25A20 variant
Carnitine-acylcarnitine translocase deficiency is a severe neonatal metabolic disorder caused by SLC25A20 variants. We report a case of sudden neonatal death in which post-mortem CT revealed diffuse fatty liver, and subsequent genetic analysis identified compound heterozygous variants in SLC25A20 , including a known variant, c.824G>A p.(Arg275Gln), and a novel nonsense variant, c.334C>T p.(Gln112Ter). These findings demonstrate the utility of post-mortem genetic analysis in determining the cause of sudden neonatal death.
- 12 June 2026
- Published by Springer Nature in Human Genome Variation
Open AccessPost-mortem diagnosis of CACT deficiency with a novel SLC25A20 variant
Carnitine-acylcarnitine translocase deficiency is a severe neonatal metabolic disorder caused by SLC25A20 variants. We report a case of sudden neonatal death in which post-mortem CT revealed diffuse fatty liver, and subsequent genetic analysis identified compound heterozygous variants in SLC25A20 , including a known variant, c.824G>A p.(Arg275Gln), and a novel nonsense variant, c.334C>T p.(Gln112Ter). These findings demonstrate the utility of post-mortem genetic analysis in determining the cause of sudden neonatal death.
- Open Access
- 31 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102569
Quantification of glycosaminoglycans in dried blood spots, and evaluation of its usefulness as a secondary newborn screening test for mucopolysaccharidoses
- 31 March 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102569
Open AccessQuantification of glycosaminoglycans in dried blood spots, and evaluation of its usefulness as a secondary newborn screening test for mucopolysaccharidoses
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Genetics
- Vol. 2026 (1)
Camptodactyly and Early‐Onset Scoliosis in Snijders Blok–Campeau Syndrome
Snijders Blok–Campeau syndrome is caused by a heterozygous CHD3 pathogenic variant, and characterized by features including macrocephaly, speech delay, hypotonia, and joint laxity. In the hereby‐presented case, a Japanese girl with Snijders Blok–Campeau syndrome displayed bilateral middle finger camptodactyly and early‐onset scoliosis, beyond the characteristic symptoms such as intellectual disability, facial abnormalities, macrocephaly, and hypotonia due to a recurrent CHD3 pathogenic variant. This case expands our knowledge of the phenotypic spectrum of Snijders Blok–Campeau syndrome.
- 1 January 2026
- Published by Wiley in Case Reports in Genetics
- Vol. 2026 (1)
Open AccessCamptodactyly and Early‐Onset Scoliosis in Snijders Blok–Campeau Syndrome
Snijders Blok–Campeau syndrome is caused by a heterozygous CHD3 pathogenic variant, and characterized by features including macrocephaly, speech delay, hypotonia, and joint laxity. In the hereby‐presented case, a Japanese girl with Snijders Blok–Campeau syndrome displayed bilateral middle finger camptodactyly and early‐onset scoliosis, beyond the characteristic symptoms such as intellectual disability, facial abnormalities, macrocephaly, and hypotonia due to a recurrent CHD3 pathogenic variant. This case expands our knowledge of the phenotypic spectrum of Snijders Blok–Campeau syndrome.
- Open Access
- 23 October 2025
- Published by Springer Nature in Human Genome Variation
- Vol. 12 (1) , 1-3
Mitochondrial dysfunction in MED13 variant-associated disease: a case of infantile spasms, cardiomyopathy and hepatomegaly
Here we report a de novo heterozygous MED13 variant (c.2503C>T, p.Pro835Ser) in an infant presenting with infantile spasms, hypertrophic cardiomyopathy and hepatomegaly. Autopsy revealed mitochondrial abnormalities in cardiac and hepatic tissues, with reduced respiratory chain complex activity. This is the first case report linking a MED13 variant to systemic mitochondrial dysfunction, suggesting a novel pathogenic mechanism.
- 23 October 2025
- Published by Springer Nature in Human Genome Variation
- Vol. 12 (1) , 1-3
Open AccessMitochondrial dysfunction in MED13 variant-associated disease: a case of infantile spasms, cardiomyopathy and hepatomegaly
Here we report a de novo heterozygous MED13 variant (c.2503C>T, p.Pro835Ser) in an infant presenting with infantile spasms, hypertrophic cardiomyopathy and hepatomegaly. Autopsy revealed mitochondrial abnormalities in cardiac and hepatic tissues, with reduced respiratory chain complex activity. This is the first case report linking a MED13 variant to systemic mitochondrial dysfunction, suggesting a novel pathogenic mechanism.
- Open Access
- 1 April 2025
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 43, 101211
Atypical case of neonatal-onset Gaucher disease type 3b: A case report
- 1 April 2025
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 43, 101211
Open AccessAtypical case of neonatal-onset Gaucher disease type 3b: A case report
- Open Access
- 4 December 2024
- Published by Springer Nature in Human Genome Variation
- Vol. 11 (1) , 1-4
Neonatal myoclonus in Bryant-Li-Bhoj syndrome associated with a novel H3F3A variant
Bryant-Li-Bhoj syndrome (BLBS; OMIM # 619720, 619721), caused by germline H3F3A and H3F3B variants encoding histone H3.3, is characterized by mild to severe developmental delay, intellectual disability, failure to thrive, muscle tone abnormalities, and dysmorphic facial features. Here, we present a Japanese patient with a novel heterozygous p.A48G variant in H3F3A, displaying previously unrecognized symptoms of neonatal myoclonus. This case helps broaden the phenotypic spectrum of BLBS.
- 4 December 2024
- Published by Springer Nature in Human Genome Variation
- Vol. 11 (1) , 1-4
Open AccessNeonatal myoclonus in Bryant-Li-Bhoj syndrome associated with a novel H3F3A variant
Bryant-Li-Bhoj syndrome (BLBS; OMIM # 619720, 619721), caused by germline H3F3A and H3F3B variants encoding histone H3.3, is characterized by mild to severe developmental delay, intellectual disability, failure to thrive, muscle tone abnormalities, and dysmorphic facial features. Here, we present a Japanese patient with a novel heterozygous p.A48G variant in H3F3A, displaying previously unrecognized symptoms of neonatal myoclonus. This case helps broaden the phenotypic spectrum of BLBS.
- Open Access
- 22 February 2024
- Published by Springer Nature in Human Genome Variation
- Vol. 11 (1) , 1-3
A severe case of cardiospondylocarpofacial syndrome with a novel MAP3K7 variant
Cardiospondylocarpofacial syndrome (CSCFS) is a congenital malformation characterized by growth retardation, facial features, short toes with carpal and tarsal fusion, extensive posterior neck vertebral fusion, congenital heart disease, and deafness. Here, we report a severe case of CSCFS with a novel variant, p.Thr187Ile, in MAP3K7. Thr187 is the main phosphorylation site for TGF-beta-activated kinase 1 encoded by MAP3K7, and this variant may cause significant abnormalities in downstream signaling.
- 22 February 2024
- Published by Springer Nature in Human Genome Variation
- Vol. 11 (1) , 1-3
Open AccessA severe case of cardiospondylocarpofacial syndrome with a novel MAP3K7 variant
Cardiospondylocarpofacial syndrome (CSCFS) is a congenital malformation characterized by growth retardation, facial features, short toes with carpal and tarsal fusion, extensive posterior neck vertebral fusion, congenital heart disease, and deafness. Here, we report a severe case of CSCFS with a novel variant, p.Thr187Ile, in MAP3K7. Thr187 is the main phosphorylation site for TGF-beta-activated kinase 1 encoded by MAP3K7, and this variant may cause significant abnormalities in downstream signaling.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15750
Hypocarnitinemia in twins after maternal pivalate‐conjugated antibiotic therapy
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15750
Hypocarnitinemia in twins after maternal pivalate‐conjugated antibiotic therapy